Not medical advice. This website is not medical advice, a diagnosis, a match to a trial, or a recommendation to join a study. Listings are plain-English rewrites of public ClinicalTrials.gov records. Whether a site is still enrolling, and whether you qualify, can only be confirmed by the study team and your clinician. Source registry: ClinicalTrials.gov. Editorial rules: methodology.
PlainTrials
RecruitingNot a traditional drug phaseinterventionalRules rewrite

Not a traditional drug phase: Positive Airway Pressure Device for Post Traumatic Stress Disorder

Substance use disorder (SUD) and posttraumatic stress disorder (PTSD) frequently co-occur and having both disorders is associated with greater psychological and functional impairment than having either disorder alone. This is especially true in residential settings where both disorders are more severe than outpatient settings.

Official registry: https://clinicaltrials.gov/study/NCT05156112 · VA Office of Research and Development · enrollment listed as 194

What this phase means

This study does not use the classic phase 1–4 drug ladder. It may be a device, a behavior program, a surgery timing study, or an early feasibility test.

Phase labels are FDA/ICH categories applied to the registry Phase field. They are not a finding that this study succeeded.

What the registry says happens

If you join, the listed intervention(s) are Positive Airway Pressure Device. The registry lists allocation as randomized. Substance use disorder (SUD) and posttraumatic stress disorder (PTSD) frequently co-occur and having both disorders is associated with greater psychological and functional impairment than having either disorder alone.

They plan to enroll about 194 people at San Diego. Taking part typically means using or being fitted with a device plus check-ins.

Official title (unrewritten)

Examining Early Intervention Obstructive Sleep Apnea Treatment on Long-Term Outcomes in Veterans With SUD/PTSD in a Residential Treatment Program

Interventions: Positive Airway Pressure Device

Primary outcome (registry wording): Change in WHO Disability Assessment Schedule 2.0 (WHODAS 2.0)

Who it is for (from inclusion criteria)

  • Ages 18 Years to any
  • a Veteran of the U.S. military or Reserve/National Guard member
  • have an Apnea Hypopnea Index (AHI) 5 per hour
  • experienced trauma that occurred in childhood or adulthood; at least one month post-trauma
  • have current DSM-5 diagnoses of substance use disorder (SUD) via Structured Clinical Interview for DSM-Substance Use Disorders (SCID-SUD) module with a minimum 20 days of substance use in the last 90 days (Timeline Follow-back)
  • Full post-traumatic stress disorder (PTSD) diagnosis via clinician administered post-traumatic stress disorder (PTSD) scale
  • are literate in English
  • are on the post-traumatic stress disorder (PTSD) track of the Substance Abuse Residential Rehabilitation Treatment Program (SARRPT) unit

Public study contact (from the registry)

Peter Colvonen, PhD

(858) 552-8585

peter.colvonen@va.gov

Published on ClinicalTrials.gov. Contact them as a possible participant. They decide eligibility.

Sites listed on ClinicalTrials.gov

1 listed

Related recruiting trials in this snapshot

RecruitingNot a traditional drug phaseChicago, Illinois
Not a traditional drug phase: real iTBS for Mild Traumatic Brain Injury

This study will determine (i) the magnitude of immediate and sustained effects of a current clinical standard interactive computer attention processing training (APT) when combined with intermittent theta burst stimulation (iTBS), a type of repetitive transcranial magnetic stimulation and (ii) determine how APT + iTBS changes the neurocognitive system of attention in individuals with persistent attention deficits related to mTBI +/- PTSD.

NCT03819608 · Official ClinicalTrials.gov record · Northwestern University

RecruitingNot a traditional drug phaseRichmond, Virginia
Not a traditional drug phase: Antioxidant for Peripheral Vascular Diseases

The purpose of this research study is to examine the role oxidants, substances produced in the blood that can damage blood vessel function, may play in blood vessel function in healthy individuals as well as individuals with mental health disorders (posttraumatic stress disorder (PTSD) and/or generalized anxiety disorder (GAD)).

NCT04916327 · Official ClinicalTrials.gov record · Virginia Commonwealth University

FAQ about this NCT record

Is NCT05156112 still recruiting?

The sponsor posted status “Recruiting” on ClinicalTrials.gov at last ingest. Sites can pause independently. Confirm with the official record and the listed contact.

What phase is NCT05156112?

Not a traditional drug phase. Phase labels are FDA/ICH categories applied to the registry Phase field. They are not a finding that this study succeeded.

Can PlainTrials tell me if I qualify for NCT05156112?

No. The inclusion and exclusion lists on this page are readable extracts of the public eligibility block. Only the study team can screen you.

How to read a ClinicalTrials.gov record · Questions to ask the coordinator · Glossary